Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2026-04-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2025年度独立董事述职报告（刘来平）
Regulatory Filings Classification · 75% confidence The document is an annual performance report (‘述职报告’) by an independent director, detailing his duties, meeting attendance, major decisions, and governance oversight for the year 2025. It is not the company’s full Annual Report, not an earnings release, nor a management discussion. It does not announce board or management changes but rather summarizes the independent director’s activities. This type of filing does not match any specialized category and is best classified under the general regulatory filings fallback category (RNS).
2026-04-20 Chinese
董事薪酬管理制度（2026年4月）
Remuneration Information Classification · 91% confidence The document is titled "董事薪酬管理制度" (Board Director Compensation Management System) and lays out the detailed policy for the compensation, incentive mechanisms, pay standards, adjustment rules, recovery clauses, and approval procedures for directors. This falls squarely under detailed reporting of director remuneration policies. It is not an announcement of a report, not minutes or voting results, and not a standard annual or interim financial report. It corresponds to the Remuneration Information category, specifically detailing compensation for directors and senior management. Thus it should be classified as DEF 14A (Remuneration Information).
2026-04-20 Chinese
2025年度募集资金存放、管理与使用情况的专项报告
Regulatory Filings Classification · 85% confidence The document is a detailed “专项报告” (special report) on the storage, management and use of previously raised funds (募集资金) by Shenzhen XianLiketai Pharmaceutical Co., Ltd. It is not a direct financial earnings release, call transcript, board change announcement, or new share issuance notice. It is a regulatory‐mandated follow‐up disclosure on the use of financing proceeds, which does not fit cleanly into the more specific categories (CAP is for new fundraising/structure updates, SHA is for share issuances, DIV for dividends, etc.). Therefore, it falls under the fallback “Regulatory Filings” category.
2026-04-20 Chinese
关于增加套期保值型金融衍生品业务交易额度的可行性分析报告
Regulatory Filings Classification · 55% confidence The document is a detailed feasibility analysis report prepared by the company’s board (深圳信立泰药业股份有限公司董事会) concerning the proposed increase of its hedging financial derivatives transaction quota. It is not an earnings release, annual or interim report, proxy statement, dividend notice, or other well‐defined category in our taxonomy. It does not announce a board change, share issue, M&A, etc. It is a standalone corporate disclosure/filing and falls under the general “Regulatory Filings” fallback category (RNS).
2026-04-20 Chinese
2026年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2026年第一季度报告' (2026 First Quarter Report) for Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains comprehensive financial statements including the Consolidated Balance Sheet, Consolidated Income Statement, and Consolidated Cash Flow Statement, along with management's analysis of financial data. It is a full quarterly financial report, not an announcement or summary, and meets the criteria for an Interim/Quarterly Report. Q1 2026
2026-04-20 Chinese
2025年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 73% confidence The document is a standalone summary table of related‐party non‐operating fund occupations and other related transactions (“非经营性资金占用及其他关联资金往来情况汇总表”) for the 2025 period by Shenzhen Salubris Pharma. It is very short (under 5,000 characters), contains only tabular disclosure, and does not constitute a full annual or interim report, nor is it an announcement of a meeting or dividend. It appears to be a mandatory regulatory disclosure of related‐party transactions filed separately. Therefore, it fits the fallback category for miscellaneous regulatory filings (RNS).
2026-04-20 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.